Skip to main content
Pharmafile

Is the Current EU Legal Framework for Orphan Medicines Fit for Purpose?

Autumn 2019
Authors
Dr. Chris Boyle

Maria Isabel Manley, partner and head of the UK Global Life Sciences Practice, and Chris Boyle, associate, at Sidley, discuss the impact of regulatory frameworks on medicines for rare diseases.

View Article

Contacts

Boyle, Chris
Partner

Capabilities

Suggested News & Insights

2026 Momentum Food and Beverage ExchangeOctober 6-7, 2026
Sponsorships
Sidley Represents Telix Pharmaceuticals in Its US$1.65 Billion Merger With ITMOctober 5, 2026
Announcements
Most-Favored-Nation Drug Pricing for Medicare Part B Significantly Narrowed in Final RuleOctober 5, 2026
Global Life Sciences Update
Sidley Represents Jiangsu Hengrui in Connection With US$2.6 Billion Licensing Agreement With Novo NordiskOctober 1, 2026
Announcements
Sidley Represents Pyxis Oncology in an up to US$282.6 Million Public OfferingOctober 1, 2026
Announcements
Sidley Represents Jiangsu Nhwa Pharmaceutical in Its US$517.5 Million Licensing Transaction With SomniveraSeptember 30, 2026
Announcements